Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;27(1):28-35.
doi: 10.1111/bdi.13501. Epub 2024 Sep 16.

Effects of long-term lithium therapy on kidney functioning in mood disorders: A population-based historical cohort study

Ajay K Parsaik  1 , Aanchal Chaudhary  2 , Shivy Sharma  2 , Brooke Ellen Delgoffe  3 , Rachel Gabor  3 , Balwinder Singh  4
Affiliations

Effects of long-term lithium therapy on kidney functioning in mood disorders: A population-based historical cohort study

Ajay K Parsaik et al. Bipolar Disord. 2025 Feb.

Abstract

Aims: Lithium is Food and Drug Administration-approved for bipolar disorder (BD) and is also used in depressive disorders but is underutilized due to concerns about chronic kidney disease (CKD). We explored clinical and demographic profiles of patients on long-term lithium therapy (LTLT) and assessed kidney function. Our aims were to identify the predictors for CKD stage ≥3 and the impact of lithium discontinuation post-CKD diagnosis.

Methods: We conducted a population-based historical cohort study of adult patients with mood disorders on LTLT at the Marshfield Clinical Health System from 1990 to 2019. Data on lithium therapy and kidney-related information (estimated glomerular filtration rate and CKD) were extracted from electronic medical records.

Results: Among 1603 patients with mood disorders (mean age 42.1 years, 60% females), 15.3% (n = 246) developed CKD stage ≥3. Patients without CKD were on lithium for 4.5 years, compared to 6.6 years for those with CKD. Hypertension, age, and BD were significant CKD risk factors. Kidney function declined linearly with lithium duration, returning to pre-treatment trajectory in patients without CKD but showed no improvement in those with CKD after lithium discontinuation.

Conclusion: The findings suggest that CKD occurs in 15% of patients with mood disorder receiving LTLT, with its progression potentially influenced by existing comorbidities rather than lithium alone. These results underscore the importance of monitoring kidney function in patients on LTLT and considering individual risk factors for CKD development. In patients who developed CKD, Li discontinuation did not impact change in kidney function.

Keywords: bipolar disorder; comorbidities; kidney function; lithium; mood disorder.

PubMed Disclaimer

References

REFERENCES

    1. Ercis M, Ozerdem A, Singh B. When and how to use lithium augmentation for treating major depressive disorder. J Clin Psychiatry. 2023;84(2):23ac14813.
    1. Singh B, Yocum AK, Strawbridge R, et al. Patterns of pharmacotherapy for bipolar disorder: a GBC survey. Bipolar Disord. 2024;26(1):22‐32.
    1. Pahwa M, Singh B. Lithium in patients with chronic kidney disease – to continue versus discontinue? Bipolar Disord. 2022;24(5):549‐550.
    1. Pahwa M, Singh B. Lithium therapy in patients with chronic kidney disease – a clinical dilemma? Eur Neuropsychopharmacol. 2020;34:87.
    1. Bocchetta A, Ardau R, Carta P, et al. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross‐sectional study. BMC Med. 2013;11:33.